Publications
Soon CW, Algazi AP, Cha EN, Daud AI. New horizons in melanoma treatment: targeting molecular pathways. The Ochsner journal. 2010. PMID: 21603363
Armstrong EJ, Bhave P, Wong D, Ursell PC, Kaplan L, Yeghiazarians Y, Ai WZ. Left ventricular rupture due to HIV-associated T-cell lymphoma. Texas Heart Institute journal. 2010. PMID: 20844622
Logan AC, Goodnough LT. Recombinant factor VIIa: an assessment of evidence regarding its efficacy and safety in the off-label setting. Hematology. American Society of Hematology. Education Program. 2010. PMID: 21239786
Logan AC, Goodnough LT. Recombinant factor VIIa: an assessment of evidence regarding its efficacy and safety in the off-label setting. Hematology. American Society of Hematology. Education Program. 2010. PMID: 21239786
Greenberg S, Rugo HS. Triple-negative breast cancer: role of antiangiogenic agents. Cancer journal (Sudbury, Mass.). 2010. PMID: 20164688
Kim TK, Billard MJ, Wieder ED, McIntyre BW, Komanduri KV. Co-engagement of alpha(4)beta(1) integrin (VLA-4) and CD4 or CD8 is necessary to induce maximal Erk1/2 phosphorylation and cytokine production in human T cells. Human immunology. 2010. PMID: 19815047
Engstrom PF, Arnoletti JP, Benson AB, Berlin JD, Berry JM, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J, Fuchs C, Grem JL, Knol JA, Leong LA, Lin E, Mulcahy MF, Rohren E, Ryan DP, Saltz L, Shibata D, Skibber JM, Small W, Sofocleous C, Thomas J, Venook AP, Willett C, NCCN. NCCN clinical practice guidelines in oncology. Anal carcinoma. Journal of the National Comprehensive Cancer Network : JNCCN. 2010. PMID: 20064293
Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. The oncologist. 2010. PMID: 21115576
Lencioni R, Chen XP, Dagher L, Venook AP. Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved? The oncologist. 2010. PMID: 21115580
Ehrlich LI,* Oh DY,* Weissman IL, Lewis RS. *co-first author.. Differential contribution of chemotaxis and substrate restriction to segregation of immature and mature thymocytes Immunity.. 2009. PMID:
Shah NP. Fine-tuning targeted therapy of CML. Blood. 2009. PMID: 19965702
Shum AK, DeVoss J, Tan CL, Hou Y, Johannes K, O'Gorman CS, Jones KD, Sochett EB, Fong L, Anderson MS. Identification of an autoantigen demonstrates a link between interstitial lung disease and a defect in central tolerance. Science translational medicine. 2009. PMID: 20368189
Ashworth A. Familial breast cancer: the first linkage. The Lancet. Oncology. 2009. PMID: 19959078
Geyer FC, Kushner YB, Lambros MB, Natrajan R, Mackay A, Tamber N, Fenwick K, Purnell D, Ashworth A, Walker RA, Reis-Filho JS. Microglandular adenosis or microglandular adenoma? A molecular genetic analysis of a case associated with atypia and invasive carcinoma. Histopathology. 2009. PMID: 19922592
Mawad R, Hsieh A, Damon L. Graft-versus-host disease presenting with pancytopenia after en bloc multiorgan transplantation: case report and literature review. Transplantation proceedings. 2009. PMID: 20005417
Damon LE, Damon LE. Mobilization of hematopoietic stem cells into the peripheral blood. Expert review of hematology. 2009. PMID: 21082960
Cigall Kadoch, Valerie D. Wong, Tara Rambaldo, William Hyun, Clifford Lowell, James Rubenstein. Macrophage Polarization and Acquired Resistance to Rituximab in CNS Lymphoma. Blood. 2009. PMID:
Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, Lacasce AS, Blum KA, Byrd JC, Kelly M, Stock W, Linker CA, Canellos GP. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009. PMID: 19917845
Rosenbluth JM, Johnson K, Tang L, Triplett T, Pietenpol JA. Evaluation of p63 and p73 antibodies for cross-reactivity. Cell cycle (Georgetown, Tex.). 2009. PMID: 19855172
Burnell M, Levine MN, Chapman JA, Bramwell V, Gelmon K, Walley B, Vandenberg T, Chalchal H, Albain KS, Perez EA, Rugo H, Pritchard K, O'Brien P, Shepherd LE. Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009. PMID: 19901117